Tracer library / [68Ga]TATE-46

[68Ga]TATE-46

Also written as [Ga-68]Ga-TATE-46

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Neuroendocrine neoplasms Preclinical only, no clinical indication yet Receptor expression phenotyping

What it is

Compound class: Dual-target somatostatin analog-FAPI heterodimer (SSTR2/FAP-targeting peptide-quinoline conjugate)
Target / mechanism: Dual targeting of SSTR2 and FAP PMID 39770488
Clinical application: Neuroendocrine tumors (NETs) expressing SSTR2 and FAP PMID 39770488
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	>95%	TATE-46	39770488 2024 Pharmaceuticals (Basel) During the labeling process, the generator was rinsed with 2 mL of 0.05 M HCl, and the waste solution was discarded.

Need this precursor?We can point you to suppliers for [68Ga]TATE-46, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39770488. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 39770488: 'Preclinical Study of a Dual-Target Molecular Probe Labeled with 68Ga Targeting SSTR2 and FAP.'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 39770488.